From the dual function lead AP2238 to AP2469, a multi-target-directed ligand for the treatment of Alzheimer's disease

Pharmacology Research and Perspectives

Volumn 2, Issue 2, 2014, Pages

  Tarozzi, Andrea ^a   Bartolini, Manuela ^a   Piazzi, Lorna ^a,b   Valgimigli, Luca ^a   Amorati, Riccardo ^a   Bolondi, Cecilia ^a   Djemil, Alice ^a   Mancini, Francesca ^a   Andrisano, Vincenza ^a   Rampa, Angela ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b INSTITUTE OF CHEMICAL RESEARCH OF CATALONIA ICIQ   (Spain)

Author keywords

Alzheimer's disease; anti inflammatory properties; catechol derivative; multi target ligand; neuroprotective properties; amyloid peptide

Indexed keywords

ACETYLCHOLINESTERASE; BETA SECRETASE 1; CHOLINESTERASE; DUAL FUNCTION LEAD; LEAD; LIGAND; OLIGOMER; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; ANTIOXIDANT ASSAY; ARTICLE; BRAIN CELL CULTURE; CYTOSOLIC FRACTION; CYTOTOXICITY; ELEMENTAL ANALYSIS; ENZYME ACTIVITY; ENZYME INHIBITION ASSAY; HUMAN; INFLAMMATION; MELTING POINT; NEUROPROTECTION; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 85029564767     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.23     Document Type: Article

References (50)

1. Ajit D, Udan ML, Paranjape G, Nichols MR (2009). Amyloid-beta(1-42) fibrillar precursors are optimal for inducing tumor necrosis factor-alpha production in the THP-1 human monocytic cell line. Biochemistry 48: 9011–9021.
2. Amorati R, Valgimigli L (2012). Modulation of the antioxidant activity of phenols by non-covalent interactions. Org Biomol Chem 10: 4147–4158.
3. Amorati R, Pedulli GF, Valgimigli L, Attanasi OA, Filippone P, Fiorucci C, et al. (2001). Absolute rate constants for the reaction of peroxyl radicals with cardanol derivatives. J Chem Soc Perkin Trans 2: 2142–2146.
4. Amorati R, Pedulli GF, Cabrini L, Zambonin L, Landi L (2006). Solvent and pH effects on the antioxidant activity of caffeic and other phenolic acids. J Agric Food Chem 54: 2932–2937.
5. Amorati R, Pedulli GF, Pratt DA, Valgimigli L (2010). TEMPO reacts with oxygen-centered radicals under acidic conditions. Chem Commun 46: 5139–5141.
6. Amorati R, Pedulli GF, Valgimigli L (2011). Kinetic and thermodynamic aspects of the chain-breaking antioxidant activity of ascorbic acid derivatives in non-aqueous media. Org Biomol Chem 9: 3792–3800.
7. Arias E, Gallego-Sandín S, Villarroya M, García AG, López MG (2005). Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors. J Pharmacol Exp Ther 315: 1346–1353.
8. Bartolini M, Bertucci C, Bolognesi ML, Cavalli A, Melchiorre C, Andrisano V (2007). Insight into the kinetic of amyloid beta (1-42) peptide self-aggregation: elucidation of inhibitors' mechanism of action. ChemBioChem 8: 2152–2161.
9. Block ML, Zecca L, Hong JS (2007). Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8: 57–69.
10. Bobba A, Petragallo VA, Marra JS. (2010). Alzheimer's proteins, oxidative stress, and mitochondrial dysfunction interplay in a neuronal model of Alzheimer's disease. Int J Alzheimers Dis 2010: 621870. doi: 10.4061/2010/621870
11. Burton GW, Doba T, Gabe EJ, Hughes L, Lee FL, Prasad L, et al. (1985). Autoxidation of biological molecules. 4. Maximizing the antioxidant activity of phenols. J Am Chem Soc 107: 7053–1065.
12. Butterfield DA, Sultana R (2011). Methionine-35 of aβ(1-42): importance for oxidative stress in Alzheimer disease. J Amino Acids 2011: 198430.
13. Butterfield DA, Drake J, Pocernich C, Castegna A (2001). Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med 7: 548–554.
14. Citron M (2002). Beta-secretase as a target for the treatment of Alzheimer's disease. J Neurosci Res 70: 373–379.
15. Clementi ME, Marini S, Coletta M, Orsini F, Giardina B, Misiti F (2005). Abeta(31-35) and Abeta(25-35) fragments of amyloid beta-protein induce cellular death through apoptotic signals: role of the redox state of methionine-35. FEBS Lett 579: 2913–2918.
16. Dheen ST, Jun Y, Yan Z, Tay SS, Ling EA (2005). Retinoic acid inhibits expression of TNF-alpha and iNOS in activated rat microglia. Glia 50: 21–31.
17. Di Giovanni S, Eleuteri S, Paleologou KE, Yin G, Zweckstetter M, Carrupt PA, et al. (2010). Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity. J Biol Chem 285: 14941–14954.
18. Ellman GL, Courtney KD, Andres V, Featherstone RM (1961). A new rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7: 88–95.
19. Estrada LD, Soto C (2007). Disrupting β-Amyloid aggregation for Alzheimer's disease treatment. Curr Topics Med Chem 7: 115–126.
20. Fine RE (1999). The biochemistry of Alzheimer disease. Alzheimer Dis Assoc Disord 13: S82–87.
21. Fu H, Li W, Luo J, Lee NT, Li M, Tsim KW, et al. (2008). Promising anti-Alzheimer's dimer bis(7)-tacrine reduces beta-amyloid generation by directly inhibiting BACE-1 activity. Biochem Biophys Res Commun 366: 631–636.
22. Glabe CG (2006). Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging 27: 570–575.
23. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010). Mechanisms underlying inflammation in neurodegeneration. Cell 140: 918–934.
24. Guo T, Hobbs DW (2006). Development of BACE1 inhibitors for Alzheimer's disease. Curr Med Chem 13: 1811–1829.
25. Hardy J, Selkoe DJ (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353–356.
26. Hills ID, Vacca JP (2007). Progress toward a practical BACE-1 inhibitor. Curr Opin Drug Discov Devel 10: 383–391.
27. Huong VT, Shimanouchi T, Shimauchi N, Yagi H, Umakoshi H, Goto Y, et al. (2010). Catechol derivatives inhibit the fibril formation of amyloid-beta peptides. J Biosci Bioeng 109: 629–634.
28. Klegeris A, McGeer PL (2000). Interaction of various intracellular signaling mechanisms involved in mononuclear phagocyte toxicity toward neuronal cells. J Leukoc Biol 67: 127–133.
29. Kowall NW (1999). Alzheimer disease 1999: a status report. Alzheimer Dis Assoc Disord 13: S11–S16.
30. LeVine H 3rd (1993). Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci 2: 404–410.
31. Maezawa I, Hong HS, Wu HC, Battina SK, Rana S, Iwamoto T, et al. (2006). A novel tricyclic pyrone compound ameliorates cell death associated with intracellular amyloid-beta oligomeric complexes. J Neurochem 98: 57–67.
32. Mancini F, Naldi M, Cavrini V, Andrisano V (2007). Multiwell fluorometric and colorimetric microassays for the evaluation of beta-secretase (BACE-1) inhibitors. Anal Bioanal Chem 388: 1175–1183.
33. Naiki H, Higuchi K, Nakakuki K, Takeda T (1991). Kinetic analysis of amyloid fibril polymerization in vitro. Lab Invest 65: 104–110.
34. Pajouhesh H, Lenz RG (2005). Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2: 541–553.
35. Piazzi L, Rampa A, Bisi A, Gobbi S, Belluti F, Cavalli A, et al. (2003). ω-3-(4-{[Benzyl(Methyl)Amino]-Methyl}Phenyl)-6,7-Dimethoxy-2H-2-Chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation a dual function lead for Alzheimer's disease therapy. J Med Chem 46: 2279–2282.
36. Piazzi L, Cavalli A, Belluti F, Bisi A, Gobbi S, Rizzo S, et al. (2007). Estensive SAR and computational studies of 3-(4-{[Benzyl(methyl)amino]methyl}-phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) derivatives. J Med Chem 50: 4250–4254.
37. Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW (1995). Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J Neurochem 64: 253–265.
38. Polazzi E, Monti B (2010). Microglia and neuroprotection: from in vitro studies to therapeutic applications. Prog Neurobiol 92: 293–315.
39. Rauk A (2008). Why is the amyloid beta peptide of Alzheimer's disease neurotoxic? Dalton Trans 14: 1273–1282.
40. Selkoe DJ (1993). Physiological production of the beta-amyloid protein and the mechanism of Alzheimer's disease. Trends Neurosci 16: 403–409.
41. Selkoe DJ (1994). Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci 17: 489–517.
42. Shimmyo Y, Kihara T, Akaike A, Niidome T, Sugimoto H (2008). Flavonols and flavones as BACE-1 inhibitors: structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features. Biochim Biophys Acta 1780: 819–825.
43. Talaga P (2001). β-Amyloid aggregation inhibitors for the treatment of Alzheimer's disease: dream or reality? Mini rewiews Med. Chem 1: 175–186.
44. Tamagno E, Guglielmotto M, Aragno M, Borghi R, Autelli R, Giliberto L, et al. (2008). Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein. J Neurochem 104: 683–695.
45. Tarozzi A, Merlicco A, Morroni F, Bolondi C, Di Iorio P, Ciccarelli R, et al. (2010a). Guanosine protects human neuroblastoma cells from oxidative stress and toxicity induced by Amyloid-beta peptide oligomers. J Biol Regul Homeost Agents 24: 297–306.
46. Tarozzi A, Morroni F, Merlicco A, Bolondi C, Teti G, Falconi M, et al. (2010b). Neuroprotective effects of cyanidin 3-O-glucopyranoside on amyloid beta (25-35) oligomer-induced toxicity. Neurosci Lett 473: 72–76.
47. Tarozzi A, Morroni F, Bolondi C, Sita G, Hrelia P, Djemil A, et al. (2012). Neuroprotective effects of erucin against 6-hydroxydopamine-induced oxidative damage in a dopaminergic-like neuroblastoma cell line. Int J Mol Sci 13: 10899–10910.
48. Valgimigli L, and Pratt DA. (2012). Antioxidants in chemistry and biology. Pp. 1623–1677 in C. Chatgilialoglu and A. Studer, eds. Encyclopedia of radicals in chemistry, biology and materials. John Wiley & Sons Ltd, Chichester, U.K.
49. Wenlock MC, Austin RP, Burton P, Davis AM, Leeson PD (2003). A comparison of physicochemical property profiles of development and marketed oral drugs. J Med Chem 46: 1250–1256.
50. Yates SL, Burgess LH, Kocsis-Angle J, Antal JM, Dority MD, Embury PB, et al. (2000). Amyloid beta and amylin fibrils induce increases in proinflammatory cytokine and chemokine production by THP 1 cells and murine microglia. J Neurochem 74: 1017–1125.